Literature DB >> 12174920

Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen.

Nigel J Bundred1, Elizabeth Anderson, Robert I Nicholson, Mitchell Dowsett, Michael Dixon, John F Robertson.   

Abstract

BACKGROUND: This study was performed to determine whether drug action on breast tumours could also be analysed using a cell turnover index (CTI), a composite measurement of both proliferation and apoptosis.
MATERIALS AND METHODS: Data were obtained from a randomized, placebo-controlled trial comparing three single doses (50, 125 and 250 mg) of intramuscular fulvestrant (Faslodex, previously known as ICI 182,780) with oral tamoxifen 20 mg/day for 14-21 days in women with early, operable, ER-positive breast cancer. CTI was calculated as the ratio of the proliferation index to the apoptotic index.
RESULTS: Fulvestrant 250 mg significantly reduced CTI compared with both placebo (p = 0.0003) and tamoxifen (p = 0.026). The effect on CTI with tamoxifen was not significantly different from that with placebo.
CONCLUSION: This study suggests that CTI may be a useful indicator of drug action on breast tumour growth. A significant reduction in growth was found with fulvestrant 250 mg compared with tamoxifen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174920

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

Review 2.  Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.

Authors:  Jamie D Croxtall; Kate McKeage
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

Review 3.  Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Authors:  Kate McKeage; Monique P Curran; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women.

Authors:  William H Goodson; Maria Gloria Luciani; S Aejaz Sayeed; Ian M Jaffee; Dan H Moore; Shanaz H Dairkee
Journal:  Carcinogenesis       Date:  2011-09-01       Impact factor: 4.944

Review 5.  Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Authors:  C K Osborne; A Wakeling; R I Nicholson
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.